There was a meaningful reduction in the risk for non-small cell lung cancer (NSCLC) recurrence or death in post-surgical patients treated with perioperative nivolumab (Opdivo) and chemotherapy ...

Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among patients with early triple-negative breast cancer (TNBC), but a 12-week ...

Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.

During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

Trisha Wise-Draper, MD, PhD, discusses anticipated data on head and neck cancers and their potential impact on the field.

A recent study published in JAMA Oncology presents promising new data on a treatment regimen beneficial to patients with a ...

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

The DEPEND study evaluated nivolumab as a neoadjuvant immunotherapy in human papilloma virus-negative locoregionally advanced head and neck cancer. Nivolumab is already an FDA approved treatment ...

Chemotherapy and immunotherapy followed by de-escalated chemoradiation showed increased survival and reduced side effects in aggressive head and neck cancers that are not associated with human ...